DOCSLIB.ORG

Improving the Lives of the People We Touch

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Improving the Lives of the People We Touch Improving the lives of the people we touch ConvaTec Group Plc Annual Report and Accounts 2018 2018 highlights Financial highlights1 Revenue Operating profit Earnings per share $1,832m +3.8% $268m +8.0% $0.11 +37.5% ,m m . ,m m . Adjusted EBIT2 Adjusted EBIT margin Adjusted earnings per share $429m -6.0% 23.4.% $0.16 m . . m . . 1. Certain financial measures in this Annual Report and Accounts, including adjusted performance measures above, are not prepared in accordance with IFRS. All adjusted performance measures are reconciled to the most directly comparable measure prepared in accordance with IFRS on pages 66 to 71. 2. Adjusted EBIT is equivalent to adjusted operating profit as reconciled on pages 68 to 69. Contents Overview Governance Financial statements Other information IFC Financial highlights and 72 Governance report at 124 Independent auditor’s 180 Shareholder information contents a glance report to the members 01 Introduction 73 Chairman’s governance of ConvaTec Group Plc 02 Our business at a glance letter 133 Consolidated Statement 04 Our investment case 74 Governance in action of Profit or Loss 75 Board statements and how 134 Consolidated Statement Strategic report we have applied the Code of Comprehensive Income 05 Strategic report overview 78 Leadership 135 Consolidated Statement 06 Chairman’s letter 80 Board of Directors of Financial Position 08 Chief Executive Officer’s 84 Effectiveness 136 Consolidated Statement review 86 Nomination Committee of Changes in Equity 12 Our market environment report 137 Consolidated Statement 16 Our business model 89 Accountability of Cash Flows 18 Our resources and 90 Audit and Risk Committee 138 Notes to the Consolidated relationships report Financial Statements 28 Our strategy 99 Engagement with 172 Company Balance Sheet 32 Our key performance shareholders and other 173 Company Statement of indicators stakeholders Changes in Equity 34 Risk management and our 100 Corporate Responsibility 174 Notes to the Company principal risks and Committee report Financial Statements uncertainties 102 Directors’ Remuneration 44 Viability statement report 46 Operational review 119 Directors’ report 56 Chief Financial Officer’s 123 Directors’ responsibilities review statement 59 Financial review Introduction Overview – IFC Strategic report – 05 Governance – 72 Financial statements – 124 Additional information – 180 “2018 was another challenging and disappointing year for ConvaTec. We did not deliver our financial and operational targets primarily due to ineffective execution. Following an extensive review of all aspects of our business, we immediately took action to address our underperformance. Information about our refreshed execution model is included in this Annual Report. “ConvaTec has the fundamentals to be a strong business. We are confident that our refreshed execution model, including the investments we will make in our core capabilities, will enable us to better capitalise on our strengths and market opportunities to deliver sustainable profitable growth in the medium to long term1.” Rick Anderson Chief Executive Officer 1. In the context of this Annual Report and Accounts “medium term” is two to three years and “medium to long term” is three to five years. 01 ConvaTec Group Plc Annual Report and Accounts 2018 Our business at a glance ConvaTec is a MedTech business, focused on the chronic care market, with leading positions in advanced wound care, ostomy care, continence and critical care and infusion devices. + Our Purpose We exist to improve the lives of the people we touch. 110Countries where Our Vision our products are To be recognised as the most respected and successful MedTech company worldwide. marketed and sold Our Mission We drive for excellence in all we do – anticipating and addressing our customers’ needs with advanced technologies and best-in-class products and services. Our strategy We aim to drive sales and earnings momentum by leveraging our portfolio of differentiated products and our leading positions in structurally growing markets. Our refreshed execution model is focused on four strategic drivers: Simplify, Innovate, Segment and Invest. Simplify Innovate Segment Invest Read more about our strategy on pages 28 to 31. Group reported revenue by geography 1. EMEA: 41% $747.4m 2. Americas: 51% $945.3m 3. APAC: 8% $139.4m 9,400+ Group reported revenue by franchise Employees around 1. Advanced Wound Care: 32% $587.5m 2. Ostomy Care: 29% $533.3m the world 3. Continence & Critical Care: 24% $443.0m 4. Infusion Devices: 15% $268.3m 02 ConvaTec Group Plc Annual Report and Accounts 2018 Overview – IFC Strategic report – 05 Governance – 72 No.1Our position in six We market and sell our products through our markets four franchises detailed below. Global leader Silver dressings, alginate and gelling fibre dressings, hydrocolloid dressings and Advanced Wound Care Ostomy Care Financial statements – 124 (“AWC”) Devices, accessories and disposable infusion sets for Advanced wound dressings services for people with a insulin pumps and skin care products for the stoma (a surgically-created management of acute and opening where bodily waste is chronic wounds resulting from discharged), commonly resulting US leader ongoing conditions such as from causes such as colorectal Intermittent catheter retailer diabetes and acute conditions cancer, inflammatory bowel resulting from traumatic injury disease and bladder cancer. and fecal management systems and burns. Key brands: Key brands: AQUACEL™, AQUACEL™ Ag+, Esteem™, Esteem™+, Natura™, AQUACEL™ Ag Foam, Natura™+, Stomahesive™, Additional information – 180 AQUACEL™ Ag Advantage, Durahesive™, InvisiClose™ Avelle™ System, DuoDERM™, and me+™ Sensi-Care™ and Aloe Vesta™ Continence & Critical Care Infusion Devices (“CCC”) Disposable infusion sets for Products and services for people diabetes insulin pumps, similar with urinary continence issues pumps used in continuous related to spinal cord injuries, infusion treatments for multiple sclerosis, spina bifida conditions such as Parkinson’s and other causes, and devices disease and a range of products and products used in intensive for hospital and home care units and hospital settings. healthcare markets. Key brands: Key brands: GentleCath™, Flexi-Seal™, inset™, comfort™ and neria™ UnoMeter™ and me+™ 9,400+ Corporate responsibility (“CR”) Our overall approach to CR is aimed at supporting the fulfilment of our Purpose. Read about how we do this throughout this report and Manufacturing in our Corporate Responsibility Report which is available on our plants website at www.convatecgroup.com/corporate-responsibility. Improving the lives of the 9 people we touch ConvaTec Group Plc Corporate Responsibility Report 2018 03 ConvaTec Group Plc Annual Report and Accounts 2018 Our investment case Focused on delivering sustainable profitable growth in the medium to long term. Leading market positions in large and Research and development (“R&D”) structurally growing chronic care markets capabilities Our chronic care marketplace is: In recent years we have developed and commercialised a number – Valued at c. $10 billion. of innovative products that deliver proven outcomes. We own – Growing, on average, at 4%–5% per annum over the next five an extensive IP portfolio. See pages 22 and 23 for further years due to fundamental structural trends including ageing information about our R&D capabilities, our new product populations, increasing incidence of chronic conditions and better development pipeline and our IP portfolio. access to healthcare. Our refreshed execution model aims to enhance our R&D We are the leader in six key markets and have strong brands and capabilities and strengthen our innovation pipeline and development a number of market leading products. See page 12 for further processes. See page 30 for information about how we will deploy information about our market positions. our R&D capabilities more effectively to drive our strategy. Our refreshed execution model is focused on capitalising on our market leadership positions and opportunities in the growing chronic care marketplace. Diversified, balanced business with strong Focused on delivering sustainable brands and differentiated products profitable growth Our differentiated products and technologies portfolio addresses The objective of our refreshed execution model is to better a wide range of increasingly prevalent chronic conditions. capitalise on our core strengths and market opportunities, to deliver sustainable profitable growth and long-term value for all stakeholders. Our product portfolio includes market-leading brands such as See pages 28 to 31 for further information about our strategy and AQUACEL™, Avelle™, Esteem™, Natura™, GentleCath™, Flexi-Seal™ our refreshed execution model. and neria™. We are a cash-generative business, with an adjusted cash We operate globally across all key geographies, either with a direct conversion rate of 81%.1 presence or through distribution partnerships. Establishing trust with our stakeholders and with broader society In line with our refreshed execution model we will focus on premium is key to our long-term success. This means that we must act with markets, segments and geographies to deliver the most profitable integrity and behave responsibly at all times. growth on a sustainable basis. 1. Adjusted cash conversion is reconciled on page 71. 04 ConvaTec Group Plc Annual Report and Accounts 2018 Strategic report overview Overview – IFC In this Strategic report we cover our development
Load more

Recommended publications
  • Xtrackers Etfs
    Xtrackers*/** Société d’investissement à capital variable R.C.S. Luxembourg N° B-119.899 Unaudited Semi-Annual Report For the period from 1 January 2018 to 30 June 2018 No subscription can be accepted on the basis of the financial reports. Subscriptions are only valid if they are made on the basis of the latest published prospectus of Xtrackers accompanied by the latest annual report and the most recent semi-annual report, if published thereafter. * Effective 16 February 2018, db x-trackers changed name to Xtrackers. **This includes synthetic ETFs. Xtrackers** Table of contents Page Organisation 4 Information for Hong Kong Residents 6 Statistics 7 Statement of Net Assets as at 30 June 2018 28 Statement of Investments as at 30 June 2018 50 Xtrackers MSCI WORLD SWAP UCITS ETF* 50 Xtrackers MSCI EUROPE UCITS ETF 56 Xtrackers MSCI JAPAN UCITS ETF 68 Xtrackers MSCI USA SWAP UCITS ETF* 75 Xtrackers EURO STOXX 50 UCITS ETF 80 Xtrackers DAX UCITS ETF 82 Xtrackers FTSE MIB UCITS ETF 83 Xtrackers SWITZERLAND UCITS ETF 85 Xtrackers FTSE 100 INCOME UCITS ETF 86 Xtrackers FTSE 250 UCITS ETF 89 Xtrackers FTSE ALL-SHARE UCITS ETF 96 Xtrackers MSCI EMERGING MARKETS SWAP UCITS ETF* 111 Xtrackers MSCI EM ASIA SWAP UCITS ETF* 115 Xtrackers MSCI EM LATIN AMERICA SWAP UCITS ETF* 117 Xtrackers MSCI EM EUROPE, MIDDLE EAST & AFRICA SWAP UCITS ETF* 118 Xtrackers MSCI TAIWAN UCITS ETF 120 Xtrackers MSCI BRAZIL UCITS ETF 123 Xtrackers NIFTY 50 SWAP UCITS ETF* 125 Xtrackers MSCI KOREA UCITS ETF 127 Xtrackers FTSE CHINA 50 UCITS ETF 130 Xtrackers EURO STOXX QUALITY
    [Show full text]
  • Parker Review
    Ethnic Diversity Enriching Business Leadership An update report from The Parker Review Sir John Parker The Parker Review Committee 5 February 2020 Principal Sponsor Members of the Steering Committee Chair: Sir John Parker GBE, FREng Co-Chair: David Tyler Contents Members: Dr Doyin Atewologun Sanjay Bhandari Helen Mahy CBE Foreword by Sir John Parker 2 Sir Kenneth Olisa OBE Foreword by the Secretary of State 6 Trevor Phillips OBE Message from EY 8 Tom Shropshire Vision and Mission Statement 10 Yvonne Thompson CBE Professor Susan Vinnicombe CBE Current Profile of FTSE 350 Boards 14 Matthew Percival FRC/Cranfield Research on Ethnic Diversity Reporting 36 Arun Batra OBE Parker Review Recommendations 58 Bilal Raja Kirstie Wright Company Success Stories 62 Closing Word from Sir Jon Thompson 65 Observers Biographies 66 Sanu de Lima, Itiola Durojaiye, Katie Leinweber Appendix — The Directors’ Resource Toolkit 72 Department for Business, Energy & Industrial Strategy Thanks to our contributors during the year and to this report Oliver Cover Alex Diggins Neil Golborne Orla Pettigrew Sonam Patel Zaheer Ahmad MBE Rachel Sadka Simon Feeke Key advisors and contributors to this report: Simon Manterfield Dr Manjari Prashar Dr Fatima Tresh Latika Shah ® At the heart of our success lies the performance 2. Recognising the changes and growing talent of our many great companies, many of them listed pool of ethnically diverse candidates in our in the FTSE 100 and FTSE 250. There is no doubt home and overseas markets which will influence that one reason we have been able to punch recruitment patterns for years to come above our weight as a medium-sized country is the talent and inventiveness of our business leaders Whilst we have made great strides in bringing and our skilled people.
    [Show full text]
  • Schroder UK Mid Cap Fund
    Schroder UK Mid Ca p Fund plc Half Year Report and Accounts For the six months ended 31 March 2020 Key messages – Portfolio of “high conviction” stocks aiming to provide a total return in excess of the FTSE 250 (ex-Investment Companies) Index and an attractive level of yield. – Dividend has tripled since 2007 as portfolio investments have captured the cash generative nature of investee companies, in a market where income has become an increasingly important part of our investors’ anticipated returns. – Provides exposure to dynamic mid cap companies that have the potential to grow to be included in the FTSE 100 index, which are at an interesting point in their life cycle, and/or which could ultimately prove to be attractive takeover targets. – Proven research driven investment approach based on the Manager’s investment process allied with a strong selling discipline. – Managed by Andy Brough and Jean Roche with a combined 50 years’ investment experience 1, the fund has a consistent, robust and repeatable investment proces s. 1Andy Brough became Lead Manager on 1 April 2016 . Investment objective Schroder UK Mid Cap Fund plc’s (the “Company”) investment objective is to invest in mid cap equities with the aim of providing a total return in excess of the FTSE 250 (ex -Investment Companies) Index. Investment policy The strategy is to invest principally in the investment universe associated with the benchmark index, but with an element of leeway in investment remit to allow for a conviction-driven approach and an emphasis on specific companies and targeted themes. The Company may also invest in other collective investment vehicles where desirable, for example to provide exposure to specialist areas within the universe.
    [Show full text]
  • Novo Holdings Annual Report 2020 Here
    Novo Holdings A/S Annual Report 2020 1 annual report Novo Holdings A/S Tuborg Havnevej 19 2900 Hellerup, Denmark CVR 24257630 2 Novo Holdings A/S Annual Report 2020 Content Management review 06 Letter from the Chairman and the CEO Introducing 08 Novo Holdings at a glance Novo Holdings 10 Our business model 4 12 2020 performance highlights 16 Purpose and ambition 18 People and organisation Our business 20 Investment strategy 14 34 Financial performance 2020 and outlook for 2021 38 Business and financial risk 44 Corporate governance Governance 45 Boards and Leadership Team 42 50 Responsible investments Novo Holdings A/S Annual Report 2020 3 Statements 54 Statement of comprehensive income 55 Balance sheet Financial statements 56 Equity statement 52 57 Cash flow statement 59 Notes to the financial statement Management's 84 Management’s statement statement and 82 Auditor’s report 85 Independent Auditor’s report Front page: Novo Holdings is a world-leading life science investor with a focus on creating long-term value. We invest in life science companies at all stages of development and in a broad portfolio of equity and fixed income securities. 4 Novo Holdings A/S Annual Report 2020 Management review Introducing Novo Holdings Novo Holdings has a substantial portfolio of industrial biotech companies providing sustainable solutions within areas including agriculture and food production. 6 Novo Holdings A/S Annual Report 2020 Letter from the Chairman and the CEO The year 2020 was marked by the significant challenges brought about by the companies, taking its total portfolio to 10 companies. In just two years, coronavirus pandemic.
    [Show full text]
  • DATABANK INSIDE the CITY SABAH MEDDINGS the WEEK in the MARKETS the ECONOMY Consumer Prices Index Current Rate Prev
    10 The Sunday Times February 10, 2019 BUSINESS Liam Kelly LETTERS 56-year-old chairman of before Serco and others got Send your letters, including executive had the audacity to arrangements a business has. Mrs M&S awaits her love sausage housebuilder Taylor Wimpey into a pickle for overcharging SIGNALS full name and address, describe me as a “dangerous For those already using a has been keen to link his the government to tag AND NOISE . to: The Sunday Times, threat” to the company. supported package, there is Much derision for Marks & Prufrock wonders name to several recruitment criminals, ushering in a 1 London Bridge Street, Calantzopoulos has likely to be no additional cost. Spencer after the high street whether Rowe, 51, plans to processes, including the dark period for outsourcers. London SE1 9GF. Or email: spearheaded PMI’s drive for For those using spreadsheets, stalwart unveiled a heart- treat the Mrs M&S in his life — chairmanships of John Lewis Beeston knows how tricky [email protected] safer products. That doesn’t bridging products are shaped “love sausage” as a his wife, Jo, an ardent Marks Partnership and the suit hire recruitment can be: he’s on Letters may be edited make him a hypocrite, but a available at about £20 a year. treat for a romantic breakfast shopper — to a love sausage chain Moss Bros. the nominations committee realist. André is an engineer: Our MTD service is live to on Valentine’s Day. on Thursday. He has been at Taylor of the Premier League, careful, methodical, logical.
    [Show full text]
  • Your Guide Directors' Remuneration in FTSE 250 Companies
    Your guide Directors’ remuneration in FTSE 250 companies The Deloitte Academy: Promoting excellence in the boardroom October 2018 Contents Overview from Mitul Shah 1 1. Introduction 4 2. Main findings 8 3. The current environment 12 4. Salary 32 5. Annual bonus plans 40 6. Long term incentive plans 52 7. Total compensation 66 8. Malus and clawback 70 9. Pensions 74 10. Exit and recruitment policy 78 11. Shareholding 82 12. Non-executive directors’ fees 88 Appendix 1 – Useful websites 96 Appendix 2 – Sample composition 97 Appendix 3 – Methodology 100 Your guide | Directors’ remuneration in FTSE 250 companies Overview from Mitul Shah It has been a year since the Government announced its intention to implement a package of corporate governance reforms designed to “maintain the UK’s reputation for being a ‘dependable and confident place in which to do business’1, and in recent months we have seen details of how these will be effected. The new UK Corporate Governance Code, to take effect for accounting periods beginning on or after 1 January 2019, includes some far reaching changes, and the year ahead will be a period of review and change for many companies. Remuneration committees must look at how best to adapt to an expanded remit around workforce remuneration, as well as a greater focus on how judgment is used to ensure that pay outcomes are justified and supported by performance. Against this backdrop, 2018 has been a mixed year in the FTSE 250 executive pay environment. In terms of pay outcomes, the picture is relatively stable. Overall pay levels have fallen for FTSE 250 chief executives and we have seen continued momentum in companies adopting executive alignment features such as holding periods, as well as strengthening shareholding guidelines for executives.
    [Show full text]
  • FTSE Russell Publications
    2 FTSE Russell Publications 19 August 2021 FTSE 250 Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 3i Infrastructure 0.43 UNITED Bytes Technology Group 0.23 UNITED Edinburgh Investment Trust 0.25 UNITED KINGDOM KINGDOM KINGDOM 4imprint Group 0.18 UNITED C&C Group 0.23 UNITED Edinburgh Worldwide Inv Tst 0.35 UNITED KINGDOM KINGDOM KINGDOM 888 Holdings 0.25 UNITED Cairn Energy 0.17 UNITED Electrocomponents 1.18 UNITED KINGDOM KINGDOM KINGDOM Aberforth Smaller Companies Tst 0.33 UNITED Caledonia Investments 0.25 UNITED Elementis 0.21 UNITED KINGDOM KINGDOM KINGDOM Aggreko 0.51 UNITED Capita 0.15 UNITED Energean 0.21 UNITED KINGDOM KINGDOM KINGDOM Airtel Africa 0.19 UNITED Capital & Counties Properties 0.29 UNITED Essentra 0.23 UNITED KINGDOM KINGDOM KINGDOM AJ Bell 0.31 UNITED Carnival 0.54 UNITED Euromoney Institutional Investor 0.26 UNITED KINGDOM KINGDOM KINGDOM Alliance Trust 0.77 UNITED Centamin 0.27 UNITED European Opportunities Trust 0.19 UNITED KINGDOM KINGDOM KINGDOM Allianz Technology Trust 0.31 UNITED Centrica 0.74 UNITED F&C Investment Trust 1.1 UNITED KINGDOM KINGDOM KINGDOM AO World 0.18 UNITED Chemring Group 0.2 UNITED FDM Group Holdings 0.21 UNITED KINGDOM KINGDOM KINGDOM Apax Global Alpha 0.17 UNITED Chrysalis Investments 0.33 UNITED Ferrexpo 0.3 UNITED KINGDOM KINGDOM KINGDOM Ascential 0.4 UNITED Cineworld Group 0.19 UNITED Fidelity China Special Situations 0.35 UNITED KINGDOM KINGDOM KINGDOM Ashmore
    [Show full text]
  • The UK Private Equity IPO Report
    THE UK PRIVATE EQUITY IPO REPORT Private equity-backed IPOs: 1 January 2009 – 31 December 2017 IN ASSOCIATION WITH 2 | THE UK PRIVATE EQUITY IPO REPORT CONTENTS FOREWORD 03 HISTORIC ANALYSIS OF PRIVATE EQUITY-BACKED IPOS IN THE UK 04 BETWEEN 1 JANUARY 2009 AND 31 DECEMBER 2017 VOLUME AND VALUE OF PRIVATE EQUITY-BACKED IPOS LISTING IN THE UK 05 TOP 10 PRIVATE EQUITY-BACKED IPOS 06 INDUSTRIES 07 FREE FLOAT 12 USE OF PROCEEDS 13 PRICING 14 PERFORMANCE 15 ANALYSIS OF ACTIVE PRIVATE EQUITY HOUSES BY SIZE 17 LOCK-UP PERIODS 18 HOLDING PERIODS 20 PRIVATE EQUITY-BACKED IPO ACTIVITY IN 2017 21 APPENDIX 23 PRIVATE EQUITY-BACKED IPOS 1 JANUARY 2009 - 31 DECEMBER 2017 23 METHODOLOGY 31 CONTACTS 32 3 | THE UK PRIVATE EQUITY IPO REPORT FOREWORD Public markets have long been an important exit route for private equity houses selling their stakes into the companies they have backed, yet little research has been conducted into how these businesses perform after they have floated. This report, published by the BVCA and PwC, provides an historic analysis of private equity-backed IPOs in the UK between 1 January 2009 and 31 December 2017. It looks at a number of metrics including the use of proceeds, pricing and performance to build a picture of the IPO market and the key trends with the market. The performance numbers are particularly revealing as they show that private equity-backed IPOs are trading on average 43.9% higher than their offer price for the period from IPO to 31 December 2017 compared to the non-private equity-backed IPOs of the same period which are trading at an average of 26.6% higher.
    [Show full text]
  • TOBAM Voting Report Meeting for GCL-POLY ENERGY HOLDINGS LTD
    TOBAM Voting report Votes Meeting for GCL-POLY ENERGY HOLDINGS LTD on 05 Jan 2018 Management ISS recommandation recommandation TOBAM Vote 1 Approve Wafer Products Supply Framework Agreement, Annual Cap and Related Transactions For For For Votes Available Voted MDP - TOBAM Anti-Benchmark All Countries World 10.00 10.00 1 TOBAM Voting report Votes Meeting for AIRASIA BHD on 08 Jan 2018 Management ISS recommandation recommandation TOBAM Vote 1 Approve Internal Reorganization For For For 1 Approve Internal Reorganization For For For Votes Available Voted MDP - TOBAM Anti-Benchmark Emerging Markets 12,860,200.00 12,860,200.00 2 TOBAM Voting report Votes Meeting for AIRASIA BHD on 08 Jan 2018 Management ISS recommandation recommandation TOBAM Vote Court-Ordered Meeting for Shareholders 1 Approve Scheme of Arrangement For For For Court-Ordered Meeting for Shareholders 1 Approve Scheme of Arrangement For For For Votes Available Voted MDP - TOBAM Anti-Benchmark All Countries World 121,700.00 121,700.00 3 TOBAM Voting report Votes Meeting for ZODIAC SA on 09 Jan 2018 Management ISS recommandation recommandation TOBAM Vote Ordinary Business 1 Approve Financial Statements and Statutory Reports For For For 2 Approve Consolidated Financial Statements and Statutory Reports For For For 3 Approve Allocation of Income and Absence of Dividends For For For 4 Acknowledge Auditors' Special Report on Related-Party Transactions Mentioning the Absence of For For For 5 Authorize Repurchase of Up to 10 Percent of Issued Share Capital For For For 6 Reelect Patrick
    [Show full text]
  • Proxy Vote Record
    Company Name Ticker Country Meeting Date Proposal Text Vote Instruction A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Receive Report of Board A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Accept Financial Statements and Statutory Reports For A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Approve Discharge of Management and Board For A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Approve Allocation of Income and Dividends of DKK 150 Per Share For A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Reelect Jim Hagemann Snabe as Director For A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Reelect Ane Maersk Mc-Kinney Uggla as Director For A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Reelect Robert Maersk Uggla as Director For A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Reelect Jacob Andersen Sterling as Director For A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Reelect Thomas Lindegaard Madsen as Director For A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Ratify PricewaterhouseCoopers as Auditors For A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Authorize Board to Declare Extraordinary Dividend For A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Approve DKK 784.9 Million Reduction in Share Capital via Share Cancellation For A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Approve Guidelines for Incentive-Based Compensation for Executive Management and Board Against A.P.
    [Show full text]
  • Meeting Details Report
    Company Name Country Meeting Date Proposal Text Vote Instruction A.D.O. Group Ltd. Israel 01-Mar-18 Elect Doron Haim Cohen as External Director For A.D.O. Group Ltd. Israel 01-Mar-18 Elect Riki Granot as External Director For A.D.O. Group Ltd. Israel 01-Mar-18 Elect Alex Hefetz as External Director Do Not Vote A.D.O. Group Ltd. Israel 01-Mar-18 Elect Barak Salomon as External Director Do Not Vote A.D.O. Group Ltd. Israel 01-Mar-18 Vote FOR if you are a controlling shareholder or have a personal interest in one or several resolutions, as indicated in the proxy card; otherwise, vote AGAINST. You Against may not abstain. If you vote FOR, please provide an explanation to your account manager A.D.O. Group Ltd. Israel 01-Mar-18 If you are an Interest Holder as defined in Section 1 of the Securities Law, 1968, vote FOR. Otherwise, vote against. Against A.D.O. Group Ltd. Israel 01-Mar-18 If you are a Senior Officer as defined in Section 37(D) of the Securities Law, 1968, vote FOR. Otherwise, vote against. Against A.D.O. Group Ltd. Israel 01-Mar-18 If you are an Institutional Investor as defined in Regulation 1 of the Supervision Financial Services Regulations 2009 or a Manager of a Joint Investment Trust Fund as For defined in the Joint Investment Trust Law, 1994, vote FOR. Otherwise, vote against. AmerisourceBergen Corporation USA 01-Mar-18 Elect Director Ornella Barra Against AmerisourceBergen Corporation USA 01-Mar-18 Elect Director Steven H.
    [Show full text]
  • Holdings—Artisan International Small-Mid Fund
    Artisan International Small-Mid Fund Holdings As of 31 March 2020 Portfolio Holdings Quantity Security Name/Description Price Book Total Market Value Book Pct Assets (%) 556,077 Abcam PLC 14.28 7,942,769.54 0.50 330,602 ACADIA Pharmaceuticals Inc 42.25 13,967,934.50 0.88 733,643 Afya Ltd 19.06 13,983,235.58 0.89 126,083 Agios Pharmaceuticals Inc 35.48 4,473,424.84 0.28 2,060,867 AIXTRON SE 8.78 18,099,561.49 1.15 52,248 Alcon Inc 51.03 2,666,321.30 0.17 41,137 ALK-Abello A/S 227.41 9,355,090.70 0.59 473,743 Alkermes PLC 14.42 6,831,374.06 0.43 1,659,119 Almirall SA 11.59 19,222,951.38 1.22 78,841 Alnylam Pharmaceuticals Inc 108.85 8,581,842.85 0.54 690,713 Altus Group Ltd 25.94 17,914,463.50 1.13 459,233 Amarin Corp PLC 4.00 1,836,932.00 0.12 774,611 Ambu A/S 24.37 18,878,174.19 1.20 137,197 Applied Therapeutics Inc 32.69 4,484,969.93 0.28 170,372 Aprea Therapeutics Inc 34.76 5,922,130.72 0.38 121,082 Argenx SE 134.93 16,337,543.38 1.03 123,052 Ariake Japan Co Ltd 62.84 7,733,059.49 0.49 136,929 ASOS PLC 14.81 2,027,698.28 0.13 514,003 Aston Martin Lagonda Global Holdings PLC 2.45 1,260,236.90 0.08 128,913 Atos SE 67.67 8,723,084.19 0.55 1,245,970 Auto Trader Group PLC 5.43 6,771,404.11 0.43 386,175 AVEVA Group PLC 43.18 16,674,996.34 1.06 1,260,800 Azbil Corp 25.98 32,755,216.69 2.07 3,465,136 B&M European Value Retail SA 3.41 11,831,480.87 0.75 156,915 Baloise Holding AG 131.26 20,596,262.63 1.30 108,140 Basler AG 41.18 4,453,444.53 0.28 316,966 Beijer Ref AB 18.01 5,708,330.96 0.36 3,602 Belimo Holding AG 6,487.29 23,367,224.49 1.48
    [Show full text]